N Hirji1, E Sykakis2, F C Lam3, R Petrarca1, S Hamada2, D Lake2. 1. 1] The Corneoplastic Unit, The Queen Victoria Hospital and Eye Bank, East Grinstead, UK [2] Department of Ophthalmology, East Surrey Hospital, Surrey, UK. 2. The Corneoplastic Unit, The Queen Victoria Hospital and Eye Bank, East Grinstead, UK. 3. 1] The Corneoplastic Unit, The Queen Victoria Hospital and Eye Bank, East Grinstead, UK [2] Ophthalmology Department, Worthing and St. Richards Hospital, Western Sussex Hospitals NHS Foundation Trust, West Sussex, UK.
Abstract
PURPOSE: Corneal collagen crosslinking (CXL) is a relatively new technique to reduce the progression of keratoconus. The technique can be performed with or without complete debridement of the corneal epithelium. We describe a novel intermediate technique involving mechanical disruption of the epithelium, and evaluate its safety and efficacy. METHODS: The case notes of 128 eyes with progressive keratoconus or iatrogenic corneal ectasia who had undergone CXL using the epithelial disruption technique were retrospectively reviewed. Thin corneas were treated with hypotonic riboflavin. All others were treated with an isotonic solution. Note was made of preoperative and postoperative parameters, including uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), refraction, endothelial cell count, and corneal tomography. Occurrence of procedure-related complications was recorded. Statistical analyses were performed using the paired sample t-test and Wilcoxon signed-rank test, with a level of P<0.05 being accepted as statistically significant. RESULTS: At 12 months, 41.8% of patients treated with isotonic riboflavin had improved UCVA and 29.7% had improved BSCVA. Only 13.4% lost lines of UCVA and 14.9% lost BSCVA. Of the patients treated with hypotonic riboflavin, at 12 months, 75% demonstrated stability of BSCVA and 25% had stable Kmax. In addition, 25% showed improved visual acuity at 12 months, and 58.3% showed regression of their Kmax. Our rate of short-term complications was comparable to studies using complete epithelial removal. CONCLUSIONS: CXL with epithelial disruption is a safe and effective treatment for keratoconus or iatrogenic corneal ectasia, and may be better tolerated by patients than the epithelium-off technique.
PURPOSE: Corneal collagen crosslinking (CXL) is a relatively new technique to reduce the progression of keratoconus. The technique can be performed with or without complete debridement of the corneal epithelium. We describe a novel intermediate technique involving mechanical disruption of the epithelium, and evaluate its safety and efficacy. METHODS: The case notes of 128 eyes with progressive keratoconus or iatrogenic corneal ectasia who had undergone CXL using the epithelial disruption technique were retrospectively reviewed. Thin corneas were treated with hypotonic riboflavin. All others were treated with an isotonic solution. Note was made of preoperative and postoperative parameters, including uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), refraction, endothelial cell count, and corneal tomography. Occurrence of procedure-related complications was recorded. Statistical analyses were performed using the paired sample t-test and Wilcoxon signed-rank test, with a level of P<0.05 being accepted as statistically significant. RESULTS: At 12 months, 41.8% of patients treated with isotonic riboflavin had improved UCVA and 29.7% had improved BSCVA. Only 13.4% lost lines of UCVA and 14.9% lost BSCVA. Of the patients treated with hypotonic riboflavin, at 12 months, 75% demonstrated stability of BSCVA and 25% had stable Kmax. In addition, 25% showed improved visual acuity at 12 months, and 58.3% showed regression of their Kmax. Our rate of short-term complications was comparable to studies using complete epithelial removal. CONCLUSIONS: CXL with epithelial disruption is a safe and effective treatment for keratoconus or iatrogenic corneal ectasia, and may be better tolerated by patients than the epithelium-off technique.
Authors: Sally Hayes; David P O'Brart; Letitia S Lamdin; James Doutch; Kostas Samaras; John Marshall; Keith M Meek Journal: J Cataract Refract Surg Date: 2008-04 Impact factor: 3.351
Authors: George D Kymionis; Dimitra M Portaliou; Dimitrios I Bouzoukis; Leejee H Suh; Aristofanis I Pallikaris; Marinos Markomanolakis; Sonia H Yoo Journal: J Cataract Refract Surg Date: 2007-11 Impact factor: 3.351
Authors: Bonnie Nga Kwan Choy; Ming Ming Zhu; Jennifer Wei Huen Shum; Wing Lau Ho; Jonathan Cheuk Hung Chan; Alex Lap Ki Ng; Jimmy Shiu Ming Lai Journal: Graefes Arch Clin Exp Ophthalmol Date: 2015-12-21 Impact factor: 3.117
Authors: Sara Crespo Millas; José Carlos López; Elena García-Lagarto; Estibaliz Obregón; Denise Hileeto; Miguel J Maldonado; J Carlos Pastor Journal: J Ophthalmol Date: 2020-07-30 Impact factor: 1.909
Authors: Ana Maria Cunha; Tiago Sardinha; Luís Torrão; Raúl Moreira; Fernando Falcão-Reis; João Pinheiro-Costa Journal: Clin Ophthalmol Date: 2020-08-14